Table 6.
Poisson regression analysis for hyposalivation, measured by stimulated whole salivary flow rates in childhood cancer survivors (n = 264).
| Variable | Number of Survivors a | Hyposalivation < 0.7 mL/min (n) | Risk Ratio | 95% CI | p |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 144 | 37 | 1.0 (ref) | ||
| Female | 120 | 45 | 1.57 | 1.10 to 2.23 | 0.013 |
| Age at diagnosis (per 1 year increase) | 264 | 82 | 0.98 | 0.94 to 1.03 | 0.442 |
| Time since diagnosis (per 10 year increase) | 264 | 82 | 0.91 | 0.71 to 1.16 | 0.433 |
| Radiotherapy dose to salivary glands | |||||
| 0 Gy b | 191 | 49 | 1.0 (ref) | ||
| >0 and ≤12 Gy | 26 | 10 | 1.74 | 0.95 to 3.20 | 0.073 |
| >12 and ≤34 Gy | 32 | 14 | 2.15 | 1.26 to 3.67 | 0.005 |
| >34 Gy | 15 | 9 | 2.25 | 1.35 to 3.76 | 0.002 |
| Chemotherapy | |||||
| No vinca alkaloids | 39 | 19 | 1.0 (ref) | ||
| Vinca alkaloids | 225 | 63 | 0.67 | 0.44 to 1.02 | 0.059 |
| No anthracyclines | 91 | 36 | 1.0 (ref) | ||
| Anthracyclines | 173 | 46 | 0.81 | 0.56 to 1.18 | 0.281 |
| No alkylating agents | 80 | 32 | 1.0 (ref) | ||
| Alkylating agents | 184 | 50 | 0.81 | 0.55 to 1.19 | 0.282 |
Gy: gray, (ref): reference category; a 7 participants were excluded from this analysis due to unclear information about radiotherapy (n = 1) and radiotherapy to salivary glands (n = 6). b Group of RT dose of 0 Gray consists of Group 1: chemotherapy (n = 185) and survivors who did receive H&N RT but not to salivary glands (n = 6).